
# **C027 R**|SOncology<sup>™</sup> Beyond Expectations

### Background


Tumor cells generate elevated levels of reactive oxygen species (ROS) and therefore exhibit increased expression and activity of critical ROS scavenging pathways, including the mitochondrial peroxide scavenging enzyme peroxiredoxin 3 (PRX3).

- PRX3 is a peroxidase responsible for metabolizing ~ 90% of mitochondrial ROS, primarily  $H_2O_2$ .
- PRX3 transcript levels are upregulated, compared to normal tissues, in approximately 50% of cancers (data from the GEPIA2 database).
- Genetic knock down of PRX3 in human tumor cells results in sensitization to apoptosis. • The mitochondria of malignant mesothelioma (MM) cells are structurally and functionally altered leading to disrupted metabolic function that supports tumor
- growth and can be therapeutically targeted (see figure below).

#### Mesothelial (Normal) cells




#### Malignant Mesothelioma cells




#### **Nucleus**

#### Mitochondria

# **RSO-021 is a Novel Mitochondrial PRX3 Inhibitor**



**RSO-021** is a novel formulation of Thiostrepton (TS) for clinical development. RSO-021 is a covalent inhibitor that inactivates PRX3 peroxidase activity through direct adduction of active site cysteine residues, in turn, inducing oxidative stress to levels incompatible with tumor cell survival.



A) EC<sub>50</sub> of RSO-021 in normal mesothelial and various mesothelioma cell lines (varying BAP1 expression). B) PRX3 knock down with siRNA significantly reduces MM (HM cell linepleural biphasic) proliferation (red). Co-expression of the H<sub>2</sub>O<sub>2</sub> scavenger catalase rescues proliferation in cells lacking PRX3 expression (green and blue). **C)** Weight of residual tumors resected from mice harboring MM xenografts in the peritoneal cavity following four weeks of treatment with 20 mg/ml RSO-021 2x weekly. \*\* p<0.01


References: Cunniff B. et al. PLoS One, 2015, 10(5). & Nelson K.J. et al. Antioxidants (Basel), 2021, 10(2):150.


# RSO-021, a First-in-class Covalent Inhibitor of Mitochondrial PRX3: From Bench to Bedside

D. Fennell<sup>1,2</sup>, S. Dulloo<sup>1,2</sup>, P. Szlosarek<sup>3</sup>, F. Thistlethwaite<sup>4</sup>, S. Lord<sup>5</sup>, N. Rahman<sup>5</sup>, B. Cunniff<sup>6</sup>, J. Dzialo<sup>1</sup>, C. Poile<sup>1</sup>, R. Panchal<sup>2</sup>, J. Duncan<sup>7</sup>, P. Graham<sup>7</sup>, A. Bexon<sup>7</sup>, G. Naumov<sup>7</sup>, J. Spicer<sup>8</sup>

1. Mesothelioma Research Programme, University of Leicester, 2. University Hospitals of Leicester NHS Trust, Leicester, UK, 3. St. Bartholomew's Hospital NHS Trust, London, UK, 4. The Christie NHS Foundation Trust, Manchester, UK, 5. University of Oxford, Oxford, UK, 6. University of Vermont, Larner College of Medicine, Burlington, VT, USA, 7. RS Oncology LLC, Cambridge, MA, USA, 8. Comprehensive Cancer Centre, Guy's Hospital, King's College London, London, UK


### Malignant Pleural Effusion






Small amounts of pleural effusion in the pleural space is physiologically normal. Mesothelioma and metastatic disease to the lungs often results in build-up of excess fluid (~15% of cancers). Malignant pleural effusion (MPE) is routinely drained using an intrapleural catheter.


# **PRX3 Inhibition in Malignant Pleural Effusion**





**Tumor Spheroids** 


**Immune Cells** 




- MPE contains tumor & immune cells and makes a good translational sample.
- RSO-021 shows target inhibition in both tumor & immune cell MPE components.
- RSO-021 retains activity in a complex patient derived MPE.

# **RSO-021 Local Administration**


**RSO-021** will be administered once-a-week via an indwelling intrapleural catheter (IPC) until disease progression, unacceptable toxicity, withdrawal of consent or study termination. Prior to each dose patients will have pleural effusion drained to dryness per standard of care. After each administration the IPC is secured until next RSO-021 dosing time point.



**1**. Drain pleural effusion to dryness



**2**. Administer RSO-021 via IPC





TS retains activity in patient derived malignant pleural effusions (MPE)

A) MPE collected from patients with metastatic disease. **B-C)** Adherent tumor spheroids and nonadherent immune cells grown in MPE supernatant. **D)** Relative PRX3

- MM Cells - MPE #1 - MPE #2

10





**3**. Secure IPC

#### MITOPE Phase 1/2 Study Design Dose Expansion Phase **Dose Escalation Phase NOW RECRUITING** IP Day 1 QW 360 mg RSO-021 RPD2 IP Day 1 QW N= 3 to 6 N = Total 21 N=12 **MPE Other** MPE Other tumors IP Day 1 QW N= 3 to 6 RPD2 IP Day 1 QW N= 3 to 6 RSO-021 RPC 90 mg N = 12 N = Total 2 IP Day 1 QW N= 3 to 6 **Primary Objective:** Secondary Objectives: To assess the safety, tolerability and • Establish systemic and local PK toxicity profile of RSO-021 in • Preliminary anti-tumor activity • Evaluate respiratory function patients with MPE from any solid Redox status in translational samples

tumor type and mesothelioma

### **Key Inclusion/Exclusion Criteria**

#### **Key Inclusion Criteria**

Male or female ≥ 18 years old

ECOG performance status 0-1

Histological diagnosis of MPE caused by nonmesothelioma solid tumor (expansion cohort or mesothelioma.

MPE must be considered the priority for sympto Received at least 1 prior standard of care treatm regimen, with documented progression and no alternative available.

Resolution of all acute reversible toxic effects of therapy to Grade ≤1

Dose Escalation: Paraffin block of most recent k Dose Expansion: Fresh tumor biopsy during scre after third dose.

Adequate organ function as defined by lab value Postmenopausal or surgically sterile, or be willi practice highly effective methods of birth control Willingness and ability to comply with schedule/procedures

# **Current Study Status**

The MITOPE study initiated first patient treatment in March 2022 and has completed recruitment for the Phase 1 dose escalation portion of the trial. The dose expansion phase 2 is open for recruitment of patients at the following UK sites:

- Dr. D. Fennell Leicester
- Dr. J. Spicer Guy's Hospital, London
- Dr. S. Lord Oxford
- Dr. F. Thistlethwaite The Christie, Manchester
- Dr. K Blyth Glasgow & Clyde Hospital, Scotland

Clinicians are encouraged to refer any eligible patients to the open sites. MITOPE trial is supported by Mesothelioma UK (www.mesothelioma.uk.com), NIHR (www.nihr.ac.uk) and clinicaltrials.gov: *NCT05278975* 

For more information scan the **QR code** or contact: **MITOPE@RSOncology.com** Financial disclosures: The MITOPE study is sponsored by RS Oncology LLC.



	Key Exclusion Criteria
	Prior systemic anti-cancer or radiation therapy, or surgery within 3 weeks or 5 half-lives. Treatment with investigational product/device within 30 days.
	Previous or concurrent malignancy (some exceptions).
nly) or	Patients whose extent of tumor or loculations would render intrapleural administration incomplete and/or ineffective.
om control.	Known hypersensitivity to the active ingredient/excipient.
nent approved	Any surgical or medical condition which is likely to interfere with the results of the study or pose an additional risk in participating.
f prior	Active infection with human immunodeficiency virus (HIV).
piopsy eening and	Active infection with hepatitis B; or hepatitis C in absence of sustained virologic response
es	Pregnant or breast-feeding patients
ing to ol	Symptomatic/unstable CNS tumor or metastases and/or carcinomatous meningitis
	Use of systemic corticosteroids within 15 days or other immunosuppressive drugs within 3 weeks.

